Korea’s first homegrown obesity drug could shake up a market dominated by Mounjaro and Wegovy, an industry official said, as ...

Fractyl Health reports statistically significant reductions in weight regain following GLP-1 discontinuation, advancing its Revita treatment toward a potential FDA submission in late 2026. Key ...

Retatrutide is an experimental weight-loss drug showing promising clinical trial results. Read on to understand its potential ...

Prolactin also has a direct effect on metabolism: it increases appetite, promotes weight gain, and reduces insulin ...

Bariatric surgery reduces the risk of obesity-related cancer regardless of sex and age, according to a large Nordic registry ...

South Korea's first homegrown GLP-1 obesity drug has entered the domestic market with an aggressive pricing strategy, taking ...

Repeated attempts to lose weight and subsequent weight gain can have different consequences depending on the initial state of ...

Here’s what people wish they knew before starting an oral GLP-1 for obesity, including how to cope with the digestive ...

Pet obesity is more than extra kilos or ‘fluff’. Vets warn that excess body fat can raise the risk of diabetes, joint ...

In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting ...

President Donald Trump has repeatedly referred to GLP-1 medications as 'fat shots' or 'fat drugs,' a phrasing many doctors ...

New research shows the diabetes drug acarbose selectively blocks bacterial maltose metabolism while leaving sucrose ...